Coronary disease & ACSCross-sectional study
Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries
- Cross-sectional study
- pooled individual participant data
- nationally representative health surveys
Authors' conclusion
Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries.
Study context
- Population
- Nonpregnant adults aged 40 to 69 years in 51 low-, middle- and high-income countries, national health surveys 2013–202010,589 with cardiovascular disease (CVD) history
- Participants
- 124,505 adults
- Exposure
- Aspirin use for secondary prevention by country income group
- Outcome
- Self-reported use of aspirin for secondary prevention of CVD
Main finding
As reported in the abstract
Aspirin use among individuals with a history of CVD
- Overall pooled aspirin use for secondary prevention
- 40.3% (95% CI, 37.6%-43.0%)
Observational data: associations, not effects.
Further findings
Self-reported history of CVD
- Prevalence of self-reported CVD history
- 8.1% [95% CI, 7.6%-8.6%]
- 10 589 individuals
Original publication
Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries. JAMA. Published 22 August 2023. doi:10.1001/jama.2023.12905
Summarised from the published abstract; every number is checked against it